세계의 바이오테크놀러지 투자 성장 기회(2024년)

Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.

To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.

This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.

Table of Contents

Transformation in Global Biotech Investment

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on Global Biotech Investments

Ecosystem

• Market Scope and Segmentation
• Definitions

Growth Generator

• Growth Drivers
• Growth Restraints
• The State of the Biotech Industry-Biologics Pipeline
• State of the Biotech Industry-Biologics Industry Outlook
• Biotech M&A Investment Outlook-2024
• Biotech VC Investment Outlook-2024
• Top 3 Predictions-2024
• Top 3 Big Pharma Investment Strategies for Portfolio Remodeling
• Emerging Biotech Companies Top Trends-Impact Summary
• New Modalities Driving Precision Medicine Will Remain Attractive
• Investors Prioritizing Cardiometabolism, Oncology, CNS, and Immunology

Growth Generator: Biotech M&A

• Biotech M&A Trends
• Big Biopharma M&A Activity
• Biotech M&A Analysis by Therapeutic Segment
• Biotech M&A Analysis by Modality
• Key Biopharma M&A Targets2024

Growth Generator: Biotech VC Investment

• Biotech VC Financing Trend
• Top VC Financing Deals
• Biotech VC Deal Analysis by Funding Stage
• Biotech VC Deal Analysis by Therapeutic Segment
• Biotech VC Deal Analysis by Modality
• Biotech VC Deal Analysis by Stage of Clinical Development

Companies to Action

• Google Ventures (United States)
• ARCH Ventures (United States)
• RA Capital (United States)
• SamsaraBio Capital (United States)
• OrbiMed (United States)
• Alexandria (United States)

Growth Opportunity Universe

• Growth Opportunity 1: Acquiring Rare Disease-focused Biopharma Companies
• Growth Opportunity 2: Investing in Precision Medicine Platform Technology-based Biotech Companies
• Growth Opportunity 3: Investing in Clinical-stage Chinese Biopharma Companies

Best Practices Recognition

• Best Practices Recognition

Frost Radar

• Frost Radar

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Take the Next Step
• List of Exhibits
• Legal Disclaimer